Clinical Trial Update: Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis [NA]

View source ↗

Summary

An open-label study evaluating the efficacy of ECP in secondary progressive multiple sclerosis has terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• ECP

Snippet

Sponsor: University of Utah | Conditions: Secondary Progressive Multiple Sclerosis | NA | Status: TERMINATED | Results posted: 2019-08-14